**KEY PAPERS**


**Brown GC et al.** Spin-density-projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia. *Int Med J.* 2012; 30 May. DOI:10.1111/j.1445-5994.2012.02845.x. [Link to abstract]

**Taher AT et al.** Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia:1 year results from a prospective, randomised, double-blind, placebo-controlled study. *American Society of Haematology.* 2012; 120:970-77. [Link to abstract]


**Guidelines**

**UK Thalassaemia Society.** Standards for the clinical care of children and adults with Thalassaemia in the UK. 2016. [Link to guideline]


**Royal College of Obstetricians and Gynaecologists (UK).** Management of Beta Thalassaemia in Pregnancy Green-Top Guideline no. 66. 2014. [Link to guideline]


**The Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance.** Long-term follow-up after hematopoietic stem cell transplant general guidelines for referring physicians (April 2013) [Link to guideline]

**University Health Network - Toronto General Hospital.** Guidelines for the care of patients in UHN Red Blood Cell Disorders Program. 2012. [Link to guideline]

**Northern California Comprehensive Thalassaemia Network and Children’s Hospital, Oakland.** 2012 Thalassemia Standards of Care Guidelines. [Link to guideline]

**Diamond Blackfan Anemia Foundation, Inc.** Diamond Blackfan Anemia Chelation Therapy Fact Sheet. [Link to factsheet]

**Ho PJ et al.** Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. *Internal Medicine Journal.* 2011; 41(7): 516-24. [Link to abstract]


**Cooley’s Anemia Foundation.** 2012 Position Statement on MRI-Based Hepatic Iron Assessment Methods. [Link to article]

**Angelucci E et al.** Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. *Haematologica.* 2008;93(5):741-752. [Link to full article]


Yassin MA, et al. Satural growth and prevalence of endocrinopathies in relation to liver iron content (LIC) in adult patients with beta thalassemia major (BTM) and sickle cell disease (SCD). Acta Bio Medica Atenei Parmensis. 2018 Feb 16;89(2-5):33-40. [Link to full article]

Soliman AT, et al. Final adult height and endocrine complications in young adults with 8-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC. Acta Bio Medica Atenei Parmensis. 2018 Feb 16;89(2-5):27-32. [Link to full article]


Taher AT. Clinical utility of serum ferritin thresholds for guiding iron chelation therapy when magnetic resonance imaging is unavailable in patients with non-transfusion-dependent thalassemia response to Ang et al. British Journal of Haematology. 2017 Mar 1;176(6):989-90. [Link to full article]


Inati A, et al. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with
FERRiSCAN SCIENTIFIC PUBLICATION LIST

thalassemia major following curative stem cell transplantation. *Pediatric Blood & Cancer*. 2017 Jan 1;64(1):188-96. [Link to abstract]


Chan, WC, et al. R2* as a surrogate measure of ferriscan iron quantification in thalassemia. *Journal of Magnetic

Hernando, D, et al. Magnetic susceptibility as a B0 field strength independent MRI biomarker of liver iron overload. European J Haematol. 2011; 87(4):349-54. [Link to abstract]

House M et al. Relationship between brain R(2) and liver and serum iron concentrations in elderly men. Mag Reson Med. 2010; 63:275-81. [Link to abstract]


Pathare A et al. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 2010; 89(4):405-9. [Link to abstract]


Olynnyk JK et al. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary haemochromatosis: a new role for magnetic resonance imaging. *Am J Gastroenterol* 2005;100(4):837-841. [Link to abstract]


St Pierre TG et al. Single spin-echo proton transverse relaxometry of iron-loaded liver. *NMR Biomed* 2004;17(7):446-458. [Link to abstract]

Clark PR et al. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. *Magn Reson Imaging* 2003;21(5):519-530. [Link to abstract]

Clark PR et al. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI. *Magn Reson Med*. 2003 Mar;49(3):572-5. [Link to abstract]


**REVIEW ARTICLES**


Ruefer A, et al. Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload. *Swiss Medical Weekly*. 2017 Nov 9;147:w14550-. [Link to full article]

Paisant A, et al. MRI for the measurement of liver iron content, and for the diagnosis and follow-up of iron overload disorders. *La Presse Médicale*. 2017 Dec 1;46(12):e279-87. [Link to abstract]


Quinn, CT and TG St Pierre. MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation,


Alexiou, E. Methodologies and tools used today for measuring iron load. Thalassemia Reports, 2014. 4(3). [Link to full article]


Olivieri, NF and GM Brittenham. Management of the Thalassemias. Cold Spring Harbor Perspectives in Medicine, 2013. 3(6). [Link to full article]


Ware HM, Kwiatkowski JL. Optimal use of iron chelators in pediatric patients. Clinical Advances in Hematology & Oncology 2013, 11:433-441. [Link to full article]


Bird RJ et al. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? Internal Medicine Journal. 2012; 42:450-5. [Link to abstract]


Cao A et al. Recent advances in β-thalassemias. Pediatric Reports. 2011; 3:e17. [Link to abstract]

Tziomalos K and Perifanis V. Liver iron content determination by magnetic resonance imaging. World J Gastro. 2010. 16(13): 1587-97. [Link to abstract]


CONFERENCE PROCEEDINGS


Taheer A et al. Efficacy and safety of once-daily oral deferasirox (Exjade®) during a median of 2.7 years of treatment in heavily iron-overloaded patients with β-thalassemia. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 5409. [Link to abstract]


Pennell D et al. Efficacy and safety of Deferasirox (Exjade®) in preventing cardiac iron in patients with normal baseline cardiac iron: Results from the cardiac substudy of the EPIC trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3874. [Link to abstract]


Greenberg P et al. Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of Deferasirox (DFX/Exjade®) therapy in a cohort of myelodysplastic patients. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 5083. [Link to abstract]

Piga A et al. Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with beta-thalassemia, treated with Deferasirox (ExJade(R), ICL670). *Blood* (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2689. [Link to abstract]